Get the Stockscreener App
2.04
2.00%
0.04
Outlook Therapeutics Inc stock is traded at $2.04, with a volume of 535.55K.
It is up +2.00% in the last 24 hours and up +13.33% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.00
Open:
$2.02
24h Volume:
535.55K
Relative Volume:
0.73
Market Cap:
$68.48M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.51
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-6.42%
1M Performance:
+13.33%
6M Performance:
+2.51%
1Y Performance:
-75.54%
1-Day Range:
$1.98
$2.05
1-Week Range:
$1.98
$2.19
52-Week Range:
$0.87
$8.70
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.04 | 85.71M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Dynamic growth stocks - jammulinksnews.com
Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser
Outlook Therapeutics Inc. Stock Support and Resistance Levels You Should KnowBig Return Stock Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
Outlook Therapeutics, Inc. shares fall 2.45% after-hours amid mixed market sentiment. - AInvest
What analysts say about Outlook Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Outlook Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - PrintWeekIndia
Outlook Therapeutics to Present at the 8th Annual Ophthalmology - GuruFocus
Outlook Therapeutics Showcases Breakthrough Retina Treatment Innovation at Elite Ophthalmology Summit - Stock Titan
What drives Outlook Therapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan
Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - simplywall.st
Outlook Therapeutics(OTLK) Drops 4.15% Amid Biotech Volatility - AInvest
How Outlook Therapeutics Inc. stock performs during market volatilityCapital Doubling Tips - Newser
What makes Outlook Therapeutics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser
Outlook Therapeutics (OTLK) Soars 12.08% on Clinical Trial Success - AInvest
Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus PT from Analysts - Defense World
Outlook Therapeutics shares rise 3.12% intraday after recent Federal Circuit's Disclosure-Level Test In In Re Riggs. - AInvest
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
Outlook Therapeutics announces CEO appointment - MSN
INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Outlook Therapeutics Appoints New CEO Robert Charles Jahr - The Globe and Mail
Outlook Therapeutics Appoints Bob Jahr as CEO - citybiz
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer | OTLK Stock News - GuruFocus
Outlook Therapeutics Appoints Bob Jahr as Chief Executive Officer | OTLK Stock News - Quiver Quantitative
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):